Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139082

Published: 2020

Journal Articles

Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141882

Published: 2020

Journal Articles

Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients

Sebastià Franch-Expósito, PhD, Preethi Srinivasan, PhD, Ryan Ptashkin, MS, Chaitanya Bandlamudi, PhD, Kelly L. Bolton, MD PhD, Erika Gedvilaite, Kamal Menghrajani, MD, Diana Mandelker, MD PhD, Elizabeth Comen, MD, Larry Norton, MD, Ryma Benayed, PhD, Teng Gao, Elli Papaemmanuil, PhD, Barry S Taylor, PhD, Ross L. Levine, MD, Michael F. Berger, PhD, Ahmet Zehir, PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140868

Published: 2020

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-136212

Published: 2020

Journal Articles

Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients

Kelly L. Bolton, MD PhD, Michael Foote, MD, Justin Jee, Anton Safonov, MD, Ryan Ptashkin, MS, Sean Devlin, PhD, Erika Gedvilaite, Teng Gao, Elli Papaemmanuil, PhD, Melissa S. Pessin, MD PhD, Mini Kamboj, Joseph Vijai, PhD, Kenneth Offit, MD, Phillip Awadalla, PhD, Pradeep Nataranjan, Michael F. Berger, PhD, Larry Norton, MD, Ross L. Levine, MD, Ahmet Zehir, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143041

Published: 2020

Journal Articles

Timing the Initiation of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 573.

https://doi.org/10.1182/blood-2019-124357

Published: 2019

Journal Articles

Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma

Even H Rustad, MD, Venkata Yellapantula, PhD, Dominik Glodzik, PhD, Gunes Gundem, PhD, Daniel A. Leongamornlert, PhD, Peter J Campbell, Elli Papaemmanuil, PhD, Ola Landgren, MD PhD, Francesco Maura, MD

Blood (2019) 134 (Supplement_1): 576.

https://doi.org/10.1182/blood-2019-126392

Published: 2019

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Landscape of TP53 Mutations in MPN

Noushin Farnoud, PhD, Christopher Famulare, MS, Elli Papaemmanuil, PhD, Erin McGovern, BA, Juan Medina, MS, Juan E. Arango Ossa, BS, Raajit K. Rampal, MD PhD, Bing Li, MD, Ross L. Levine, MD, John Mascarenhas, MD, Rona Singer Weinberg, PhD, Minal A Patel, MPH, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1681.

https://doi.org/10.1182/blood-2019-132014

Published: 2019

Journal Articles

Targeted Sequencing Predicts the Development of Myeloid Malignancies and Clinical Outcome in Patients with Unexplained Cytopenia

Catherine Cargo, MB, FRCPath, Kelly Bolton, MD PhD, Tumas Beinortas, MBBS, Paul Glover, MSc, Michael Short, Alexandra Smith, PhD, Jan Taylor, PhD MSc, BSc, Paul A S Evans, PhD, Elli Papaemmanuil, PhD, Simon Crouch, PhD BA, MA, MSc

Blood (2019) 134 (Supplement_1): 1712.

https://doi.org/10.1182/blood-2019-131402

Published: 2019

Journal Articles

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Shaun Fleming, MBBS,, Cheng-Hong Tsai, MD MSc, Hartmut Döhner, MD, Konstanze Döhner, Elli Papaemmanuil, PhD, Hwei-Fang Tien, MD, PhD, John Reynolds, PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Hsin-An Hou

Blood (2019) 134 (Supplement_1): 1392.

https://doi.org/10.1182/blood-2019-128243

Published: 2019

Journal Articles

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Eleftheria Lamprianidou, Chrysoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, PhD, Anastasia Filia, Stamatia Laidou, Theodoros P. Vassilakopoulos, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, MD PhD, Evangelia Nakou, Anastasia Hadzidimitriou, PhD, George Kassiotis, Elli Papaemmanuil, PhD, Ioannis Mitroulis, Ioannis Kotsianidis

Blood (2019) 134 (Supplement_1): 2988.

https://doi.org/10.1182/blood-2019-126504

Published: 2019

Journal Articles

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Anthony V. Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Thomas Creasey, MBBS, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Christine J. Harrison, PhD FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 288.

https://doi.org/10.1182/blood-2019-123642

Published: 2019

Journal Articles

Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial

Daniel A. Leongamornlert, PhD, Emilio Barretta, Soo Lee, Thomas Creasey, MBBS, Rachel J. Mitchell, MSc, Amy A. Kirkwood, MSc, Laura Clifton-Hadley, PhDBSc, Pip Patrick, PhDMSc,MA, Peter J Campbell, Bela Wrench, MBBS, MD MRCP, FRCPath, Anthony V. Moorman, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 2743.

https://doi.org/10.1182/blood-2019-125723

Published: 2019

Journal Articles

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Thomas Creasey, MBBS, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Nicholas J. Morley, John A Snowden, BSc (Hons), MBChB, MD FRCP, FRCPath, Christine J. Harrison, PhD FRCPath, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman

Blood (2019) 134 (Supplement_1): 2746.

https://doi.org/10.1182/blood-2019-124395

Published: 2019

Journal Articles

Molecular Characteristics That Predict Response to Azacitidine Therapy

Blood (2019) 134 (Supplement_1): 4246.

https://doi.org/10.1182/blood-2019-129420

Published: 2019

Journal Articles

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Linde A Miles, PhD, Robert L Bowman, PhD, Tiffany R Merlinsky, Aik Ooi, PhD, Pedro Mendez, Christopher Famulare, MS, Minal A Patel, MPH, Kelly Bolton, MD PhD, Neil Palmisiano, MD MS, Martin P. Carroll, MD, Elli Papaemmanuil, PhD, Ahmet Zehir, PhD, Sara E. Meyer, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD

Blood (2019) 134 (Supplement_1): 913.

https://doi.org/10.1182/blood-2019-128763

Published: 2019

Journal Articles

PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes

Wenbin Xiao, MD, Aaron D Goldberg, MD PhD, Brian Ball, Christopher Famulare, MS, Friederike Pastore, MD, Martin S. Tallman, MD, Yanming Zhang, MD, Maria E Arcila, MD, Elli Papaemmanuil, PhD, Ross L. Levine, MD, Mikhail Roshal, MD PhD

Blood (2018) 132 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2018-99-118985

Published: 2018

Journal Articles

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Blood (2018) 132 (Supplement 1): 543.

https://doi.org/10.1182/blood-2018-99-116661

Published: 2018

NARROW

Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.

Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis

Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001

Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients

Timing the Initiation of Multiple Myeloma

Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Landscape of TP53 Mutations in MPN

Targeted Sequencing Predicts the Development of Myeloid Malignancies and Clinical Outcome in Patients with Unexplained Cytopenia

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Molecular Characteristics That Predict Response to Azacitidine Therapy

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only